Correlation Between Emergent Biosolutions and Neurocrine Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Emergent Biosolutions and Neurocrine Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Emergent Biosolutions and Neurocrine Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Emergent Biosolutions and Neurocrine Biosciences, you can compare the effects of market volatilities on Emergent Biosolutions and Neurocrine Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Emergent Biosolutions with a short position of Neurocrine Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Emergent Biosolutions and Neurocrine Biosciences.

Diversification Opportunities for Emergent Biosolutions and Neurocrine Biosciences

0.85
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Emergent and Neurocrine is 0.85. Overlapping area represents the amount of risk that can be diversified away by holding Emergent Biosolutions and Neurocrine Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurocrine Biosciences and Emergent Biosolutions is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Emergent Biosolutions are associated (or correlated) with Neurocrine Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurocrine Biosciences has no effect on the direction of Emergent Biosolutions i.e., Emergent Biosolutions and Neurocrine Biosciences go up and down completely randomly.

Pair Corralation between Emergent Biosolutions and Neurocrine Biosciences

Considering the 90-day investment horizon Emergent Biosolutions is expected to under-perform the Neurocrine Biosciences. In addition to that, Emergent Biosolutions is 1.58 times more volatile than Neurocrine Biosciences. It trades about -0.23 of its total potential returns per unit of risk. Neurocrine Biosciences is currently generating about -0.1 per unit of volatility. If you would invest  13,706  in Neurocrine Biosciences on December 30, 2024 and sell it today you would lose (2,390) from holding Neurocrine Biosciences or give up 17.44% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Emergent Biosolutions  vs.  Neurocrine Biosciences

 Performance 
       Timeline  
Emergent Biosolutions 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Emergent Biosolutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Neurocrine Biosciences 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Emergent Biosolutions and Neurocrine Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Emergent Biosolutions and Neurocrine Biosciences

The main advantage of trading using opposite Emergent Biosolutions and Neurocrine Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Emergent Biosolutions position performs unexpectedly, Neurocrine Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will offset losses from the drop in Neurocrine Biosciences' long position.
The idea behind Emergent Biosolutions and Neurocrine Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stocks Directory
Find actively traded stocks across global markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements